. Author manuscript; available in PMC: 2023 Mar 17.

Published in final edited form as: Ophthalmology. 2015 May 9;122(7):1426–1437. doi: 10.1016/j.ophtha.2015.04.006

Table 9.

Number of Ranibizumab Injections Received by Laser plus Ranibizumab versus Ranibizumab Alone Groups

No. of Injections By Time Point	Branch Retinal Vein Occlusion			Central Retinal Vein Occlusion
No. of Injections By Time Point	Ranibizumab ± Laser	Ranibizumab Alone	P Value	Ranibizumab ± Laser	Ranibizumab Alone	P Value
Between 24 and 48 wks	3.8 ± 0.4 (n = 20)	3.7 ± 0.5 (n = 18)	0.96	4.0 ± 0.3 (n = 18)	3.0 ± 0.4 (n = 19)	0.07
Between 48 and 96 wks	7.4 ± 0.9 (n = 17)	6.9 ± 0.7 (n = 18)	0.73	7.8 ± 0.9 (n = 16)	5.5 ± 0.7 (n = 17)	0.03
Between 96 and 144 wks	5.2 ± 1.1 (n = 17)	4.0 ± 0.8 (n = 16)	0.41	5.7 ± 1.0 (n = 15)	3.9 ± 0.7 (n = 15)	0.15
Total between 24 and 144 wks	15.6 ± 2.0 (n = 17)	14.9 ± 1.8 (n = 16)	0.79	17.9 ± 2.1 (n = 15)	12.4 ± 1.6 (n = 15)	0.05